Response Rate Profiles for Major Depressive Disorder: Characterizing Early Response and Longitudinal Nonresponse

Overview

Journal Depress Anxiety

Publisher Wiley

Date 2018 Sep 28

PMID 30260539

Citations 15

Authors

Mary E Kelley

Boadie W Dunlop

Charles B Nemeroff

Adriana Lori

Tania Carrillo-Roa

Elisabeth B Binder

Michael H Kutner

Vivianne Aponte Rivera

W Edward Craighead

Helen S Mayberg

Affiliations

Soon will be listed here.

Abstract

Background: Definition of response is critical when seeking to establish valid predictors of treatment success. However, response at the end of study or endpoint only provides one view of the overall clinical picture that is relevant in testing for predictors. The current study employed a classification technique designed to group subjects based on their rate of change over time, while simultaneously addressing the issue of controlling for baseline severity.

Methods: A set of latent class trajectory analyses, incorporating baseline level of symptoms, were performed on a sample of 344 depressed patients from a clinical trial evaluating the efficacy of cognitive behavior therapy and two antidepressant medications (escitalopram and duloxetine) in patients with major depressive disorder.

Results: Although very few demographic and illness-related features were associated with response rate profiles, the aggregated effect of candidate genetic variants previously identified in large pharmacogenetic studies and meta-analyses showed a significant association with early remission as well as nonresponse. These same genetic scores showed a less compelling relationship with endpoint response categories. In addition, consistent nonresponse throughout the study treatment period was shown to occur in different subjects than endpoint nonresponse, which was verified by follow-up augmentation treatment outcomes.

Conclusions: When defining groups based on the rate of change, controlling for baseline depression severity may help to identify the clinically relevant distinctions of early response on one end and consistent nonresponse on the other.

Citing Articles

Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response.

Dai F, Wengler K, He X, Wang J, Yang J, Parsey R Transl Psychiatry. 2025; 15(1):71.

PMID: 40025010 PMC: 11873289. DOI: 10.1038/s41398-025-03292-9.

Perspective on adolescent psychiatric illness and emerging role of microRNAs as biomarkers of risk.

Morgunova A, Teixeira M, Flores C J Psychiatry Neurosci. 2024; 49(4):E282-E288.

PMID: 39209460 PMC: 11374446. DOI: 10.1503/jpn.240072.

Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression.

Wang C, Lan X, Liu W, Zhan Y, Zheng W, Chen X Transl Psychiatry. 2024; 14(1):324.

PMID: 39107286 PMC: 11303529. DOI: 10.1038/s41398-024-03027-2.

Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression.

Prompiengchai S, Dunlop K Neuropsychopharmacology. 2024; 50(1):230-245.

PMID: 38951585 PMC: 11525717. DOI: 10.1038/s41386-024-01907-1.

Trajectories of improvement with repetitive transcranial magnetic stimulation for treatment-resistant major depression in the BRIGhTMIND trial.

Briley P, Webster L, Lankappa S, Pszczolkowski S, McAllister-Williams R, Liddle P Npj Ment Health Res. 2024; 3(1):32.

PMID: 38937580 PMC: 11211415. DOI: 10.1038/s44184-024-00077-8.

References

Tang T, DeRubeis R . Sudden gains and critical sessions in cognitive-behavioral therapy for depression. J Consult Clin Psychol. 1999; 67(6):894-904. DOI: 10.1037//0022-006x.67.6.894. View

Keller M, McCullough J, Klein D, Arnow B, Dunner D, Gelenberg A . A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000; 342(20):1462-70. DOI: 10.1056/NEJM200005183422001. View

Muthen B, Shedden K . Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics. 2001; 55(2):463-9. DOI: 10.1111/j.0006-341x.1999.00463.x. View

Mallinckrodt C, Sanger T, Dube S, DeBrota D, Molenberghs G, Carroll R . Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003; 53(8):754-60. DOI: 10.1016/s0006-3223(02)01867-x. View

Keller M . Remission versus response: the new gold standard of antidepressant care. J Clin Psychiatry. 2004; 65 Suppl 4:53-9. View

Kasper S, Spadone C, Verpillat P, Angst J . Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol. 2006; 21(2):105-10. DOI: 10.1097/01.yic.0000194375.42589.c3. View

McMahon F, Buervenich S, Charney D, Lipsky R, Rush A, Wilson A . Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006; 78(5):804-814. PMC: 1474035. DOI: 10.1086/503820. View

Serretti A, Kato M, De Ronchi D, Kinoshita T . Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2006; 12(3):247-57. DOI: 10.1038/sj.mp.4001926. View

Paddock S, Laje G, Charney D, Rush A, Wilson A, Sorant A . Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007; 164(8):1181-8. DOI: 10.1176/appi.ajp.2007.06111790. View

10.

Shelton R, Andorn A, Mallinckrodt C, Wohlreich M, Raskin J, Watkin J . Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol. 2007; 22(6):348-55. DOI: 10.1097/YIC.0b013e32821c6189. View

11.

Fava M, Rush A, Alpert J, Balasubramani G, Wisniewski S, Carmin C . Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008; 165(3):342-51. DOI: 10.1176/appi.ajp.2007.06111868. View

12.

Lekman M, Laje G, Charney D, Rush A, Wilson A, Sorant A . The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry. 2008; 63(12):1103-10. PMC: 2587308. DOI: 10.1016/j.biopsych.2007.10.026. View

13.

Mrazek D, Rush A, Biernacka J, OKane D, Cunningham J, Wieben E . SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet. 2008; 150B(3):341-51. PMC: 2660379. DOI: 10.1002/ajmg.b.30816. View

14.

Kato M, Serretti A . Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2008; 15(5):473-500. DOI: 10.1038/mp.2008.116. View

15.

Lutz W, Stulz N, Kock K . Patterns of early change and their relationship to outcome and follow-up among patients with major depressive disorders. J Affect Disord. 2009; 118(1-3):60-8. DOI: 10.1016/j.jad.2009.01.019. View

16.

Szegedi A, Jansen W, Van Willigenburg A, van der Meulen E, Stassen H, Thase M . Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009; 70(3):344-53. DOI: 10.4088/jcp.07m03780. View

17.

Frank E, Prien R, Jarrett R, Keller M, Kupfer D, Lavori P . Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991; 48(9):851-5. DOI: 10.1001/archpsyc.1991.01810330075011. View

18.

Tadic A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, Henkel V . Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord. 2009; 120(1-3):86-93. DOI: 10.1016/j.jad.2009.04.014. View

19.

Hunter A, Muthen B, Cook I, Leuchter A . Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. J Psychiatr Res. 2009; 44(2):90-8. PMC: 2925497. DOI: 10.1016/j.jpsychires.2009.06.006. View

20.

Uher R, Muthen B, Souery D, Mors O, Jaracz J, Placentino A . Trajectories of change in depression severity during treatment with antidepressants. Psychol Med. 2009; 40(8):1367-77. DOI: 10.1017/S0033291709991528. View